Peptides vs Ozempic: what the evidence shows, and why Ozempic is a peptide too

Ozempic is itself a peptide drug: its active ingredient, semaglutide, is a GLP-1 analog whose “peptide backbone is produced by yeast fermentation” (Ozempic label). In the 1,961-person STEP 1 trial, semaglutide at the 2.4 mg weekly dose sold as Wegovy cut body weight by 14.9% over 68 weeks, against 2.4% on placebo (Wilding 2021). Ozempic is FDA approved for type 2 diabetes, and Wegovy for weight management. The “research peptides” sold as alternatives, such as BPC-157, AOD-9604 and MOTS-c, are not FDA approved; the published fat-loss findings for AOD-9604 and MOTS-c come from mice, BPC-157 has none, and no published human weight-loss trial results for any of them were found on PubMed (searched 2026-10-29).

Item	Ozempic (semaglutide)	Research peptides (BPC-157, AOD-9604, MOTS-c)
US FDA status	Approved 2017-12-05 for type 2 diabetes (Drugs@FDA, NDA 209637); the same molecule is approved for weight management as Wegovy, 2021-06-04 (NDA 215256)	Not FDA approved for any use; no Drugs@FDA product (openFDA, searched 2026-10-29)
Compounding	Shortage resolved 2025-02-21 (FDA); on 2026-04-30 FDA proposed excluding semaglutide from the 503B bulks list; comments closed 2026-07-30 after an extension (FDA; Federal Register)	All three withdrawn from FDA’s Category 2 list by their nominators (FDA). On 2026-07-23–24 FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 for ulcerative colitis and MOTS-c for obesity and osteoporosis; its advice is not binding and no FDA rule has followed yet (FDA meeting page)
WADA	Not prohibited (USADA); semaglutide is in WADA’s 2027 monitoring program, which does not prohibit it (USADA 2027)	Prohibited at all times on the 2026 List: BPC-157 (S0), AOD-9604 (S2), MOTS-c (S4) (WADA 2026). The 2027 List, in force 2027-01-01, names “peptides” in general under S0 (USADA 2027)
Strongest evidence	Approved label; phase 3 RCTs (STEP 1, n=1,961; SELECT, n=17,604)	Animal (mice) for fat loss; human data limited to 3 small BPC-157 studies (n=30), none on weight
Human trials	793 registered studies list semaglutide (ClinicalTrials.gov, 2026-10-29), e.g. NCT03548935, NCT03574597	No registered weight-loss trial of BPC-157 or AOD-9604 (ClinicalTrials.gov, searched 2026-10-29)
Next regulatory step	FDA’s final determination on the 503B exclusion; no final notice in the Federal Register as of 2026-10-29	FDA rulemaking on the BPC-157 and MOTS-c votes; no rule in the Federal Register as of 2026-10-29
Last checked	2026-10-29	2026-10-29

Peptides vs Ozempic at a glance

Feature	Ozempic (semaglutide)	Research peptides
What it is	A modified GLP-1 peptide, 4113.58 g/mol	Short peptides: BPC-157, AOD-9604 (a growth hormone fragment), MOTS-c
Main target	GLP-1 receptor	Various; AMPK activation (MOTS-c, mice); fat breakdown (AOD-9604, mice)
Approved use	Type 2 diabetes; heart and kidney risk in diabetes	None
Human weight evidence	Phase 3 RCTs	No published human weight trial (PubMed, searched 2026-10-29)
Best weight result	−14.9% vs −2.4% at 68 weeks (Wegovy dose)	Lower body weight and fat in obese mice
Forms	Once-weekly injection; once-daily tablet	No approved form; AOD-9604 was injected in the mouse study
Product quality	FDA-reviewed manufacturing	Unapproved; no FDA quality review
WADA	Not prohibited; monitored	Prohibited at all times
Main safety concerns	Stomach side effects, pancreatitis, gallbladder disease, thyroid tumor warning (rodents)	Unknown in people; FDA lacks safety data

Is Ozempic a peptide?

Yes. The label calls semaglutide a GLP-1 (glucagon-like peptide-1) analog with two main changes: one protects it from DPP-4, an enzyme that breaks GLP-1 down, and a fatty side chain makes it bind to albumin in the blood, which prolongs its action so that it is injected once weekly (Ozempic label). So “peptides vs Ozempic” is really a comparison between one peptide that went through full FDA review and a group of peptides that did not.

Semaglutide is sold under three brand names. Ozempic is the weekly injection for type 2 diabetes. Wegovy carries the weight-management indication, for adults and for teenagers aged 12 and older with obesity, plus heart-risk and liver (MASH) indications (Wegovy label). Rybelsus is a once-daily tablet for type 2 diabetes, and its current label also covers Ozempic tablets for the same use (Rybelsus and Ozempic tablets label). Ozempic itself has no weight-loss indication.

What “peptides” means in this comparison

Peptides are short chains of amino acids, and some approved drugs are peptides, semaglutide among them. This page uses the word in a narrower sense: peptides sold online as “research chemicals” and promoted for fat loss without FDA approval. USADA lists products “labelled as ‘research only’ or as ‘research chemicals’” as a red flag for unapproved GLP-1 products (USADA).

It compares Ozempic with three research peptides marketed for weight, BPC-157, AOD-9604 and MOTS-c, plus tesamorelin, an approved peptide studied for belly fat. Our peptides for weight loss ranking covers the wider field tier by tier.

Benefits of Ozempic and semaglutide: what the trials show

Semaglutide’s weight-loss evidence comes from large phase 3 trials. In STEP 1, a double-blind trial of 1,961 adults without diabetes, 50.5% of people on semaglutide lost at least 15% of their body weight, against 4.9% on placebo [Human RCT, n=1,961] (Wilding 2021). The average loss was 15.3 kg.

The benefit goes beyond the scale. In SELECT, 17,604 people with heart disease and overweight or obesity but no diabetes were followed for a mean of 39.8 months: a heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide and 8.0% on placebo, a hazard ratio of 0.80 [Human RCT, n=17,604] (Lincoff 2023).

The effect lasts only while treatment continues. In STEP 4, people who switched to placebo after 20 weeks of semaglutide saw their body weight rise 6.9% over the next 48 weeks, while those who stayed on it lost another 7.9% [Human RCT, n=803] (Rubino 2021). In the STEP 1 extension, participants regained two-thirds of their lost weight within a year of stopping, and most heart-risk markers drifted back toward baseline [Human, n=327] (Wilding 2022).

These trials used the 2.4 mg weekly dose sold as Wegovy, so they describe semaglutide for weight management, not Ozempic as labeled for diabetes.

What research peptides have shown for fat loss

AOD-9604 is a fragment of human growth hormone. In obese mice, 14 days of AOD-9604 injections reduced body weight and body fat [Animal] (Heffernan 2001). No report of an AOD-9604 clinical trial is indexed on PubMed, though a 2004 drug profile there says phase IIa obesity trials were underway by 2002, and none is registered on ClinicalTrials.gov (both searched 2026-10-29). FDA says it has “no, or only limited, safety-related information” on AOD-9604 and has identified serious adverse events that may be associated with it, though causality is not clear (FDA). It is compared with an approved peptide on our AOD-9604 vs tesamorelin page.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In lab and mouse work it acted mainly on skeletal muscle and activated the energy sensor AMPK, and in mice it prevented diet-induced obesity and insulin resistance [Animal] (Lee 2015). That is an encouraging result for metabolic research, but FDA reports no human exposure data on MOTS-c products by any route. It is set against another metabolic research compound in MOTS-c vs 5-Amino-1MQ.

BPC-157 has no weight-loss study, in people or animals, on PubMed (searched 2026-10-29). A 2026 systematic review found three human studies with 30 people in total, on knee pain, bladder pain and infusion safety, and rated the certainty of evidence very low [Systematic review] (Poolton 2026).

Tesamorelin is the exception: an approved peptide (Egrifta) with a randomized trial behind it. In 412 people with HIV and abdominal fat, 26 weeks of tesamorelin cut visceral fat by 15.2%, while it rose 5.0% on placebo [Human RCT, n=412] (Falutz 2007). Its label limits it to HIV-associated lipodystrophy and states that it “is not indicated for weight loss management as it has a weight neutral effect” (Egrifta WR label).

Evidence head-to-head

Outcome	Semaglutide (Ozempic, Wegovy)	Research peptides
Body weight	Human RCT, n=1,961: −14.9% vs −2.4% (STEP 1)	Animal: AOD-9604 lowered weight in obese mice (Heffernan 2001)
Waist and belly fat	Human RCT, n=751: waist −13.0 cm at 72 weeks (SURMOUNT-5)	Tesamorelin, Human RCT, n=412: −15.2% vs +5.0% in HIV (Falutz 2007)
Blood sugar and insulin resistance	Approved label: glycemic control in type 2 diabetes (label)	Animal: MOTS-c prevented diet-induced insulin resistance in mice (Lee 2015)
Heart events	Human RCT, n=17,604: HR 0.80 (SELECT)	No human data found (PubMed, searched 2026-10-29)
Keeping weight off	Human RCT, n=803: regain after switching to placebo (STEP 4)	No human data found (PubMed, searched 2026-10-29)
Human safety	Approved label with boxed warning	BPC-157: 3 studies, n=30, very low certainty (Poolton 2026)

What is stronger than Ozempic?

The drugs with bigger weight-loss results than semaglutide are other incretin drugs, not research peptides. Tirzepatide acts on both GIP and GLP-1 receptors. In SURMOUNT-5, a head-to-head trial in adults with obesity but without type 2 diabetes, tirzepatide cut weight by 20.2% and semaglutide by 13.7% over 72 weeks [Human RCT, n=751, open-label] (Aronne 2025). Tirzepatide was approved as Zepbound on 2023-11-08 (Drugs@FDA).

Two investigational drugs posted higher numbers in their own placebo-controlled trials: retatrutide, a GIP, GLP-1 and glucagon receptor agonist, with −24.2% at 48 weeks in its 12 mg arm [Human RCT, phase 2, n=338] (Jastreboff 2023), and CagriSema, semaglutide plus the amylin analog cagrilintide, with −20.4% at 68 weeks [Human RCT, phase 3, n=3,417] (Garvey 2025). These are cross-trial numbers from different populations and trial lengths, so they cannot be ranked against each other directly. FDA states that retatrutide and cagrilintide “have not been found safe and effective for any condition” and cannot be used in compounding (FDA). Our retatrutide vs tirzepatide vs semaglutide comparison sets out the trials side by side.

Which has more evidence for which goal?

• Weight loss: semaglutide has more evidence, from phase 3 RCTs with thousands of people; the research peptides have published mouse data and no published human weight-loss results.
• Heart protection: semaglutide has more evidence, from the 17,604-person SELECT trial; no research peptide has human heart-outcome data.
• Belly fat in HIV lipodystrophy: tesamorelin has an approved label and an RCT for this use; semaglutide was not tested for it in the trials above.
• Insulin sensitivity: semaglutide has the approved diabetes label; MOTS-c has encouraging but mouse-only findings.

These are statements about evidence, not a recommendation to use any of them. A clinician who knows the person’s history is the one to decide whether any weight-loss medicine fits.

Can peptides and Ozempic be combined?

One peptide pairing has phase 3 data: CagriSema, semaglutide plus cagrilintide, with stomach side effects in 79.6% of participants against 39.9% on placebo (Garvey 2025). No controlled human study of semaglutide combined with BPC-157, AOD-9604 or MOTS-c was found on PubMed or ClinicalTrials.gov (searched 2026-10-29).

Safety and regulatory status

Ozempic. The most common side effects in at least 5% of patients are nausea, vomiting, diarrhea, abdominal pain and constipation. The label carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in people is unknown, and it must not be used by people with a personal or family history of medullary thyroid cancer or MEN 2. Other label warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar with insulin, diabetic eye complications and aspiration during anesthesia (Ozempic label). In SELECT, 16.6% stopped semaglutide because of adverse events, against 8.2% on placebo (Lincoff 2023).

Copies of semaglutide. FDA has received 990 adverse-event reports linked to compounded semaglutide (as of 2026-05-31), warns that semaglutide salt forms are different active ingredients from the approved drug, and is aware of counterfeit Ozempic in the US. It has also warned sellers of semaglutide, tirzepatide and retatrutide falsely labeled “for research purposes” (FDA).

Research peptides. FDA’s compounding review found it lacks the information to know whether BPC-157 would cause harm in people, has no human exposure data on MOTS-c, and has only limited safety information on AOD-9604 (FDA). Any advice from FDA’s July 2026 advisory committee review of BPC-157 and MOTS-c is non-binding; no rule has followed as of 2026-10-29.

Sport. GLP-1 drugs are not prohibited, and no therapeutic use exemption is needed (USADA). BPC-157 (S0), AOD-9604 (S2) and MOTS-c (S4) are prohibited at all times on the 2026 List (WADA), and S0 covers any substance with no government approval for human use (USADA). From 2027-01-01, the List names “peptides” in general under S0 (USADA 2027).

Anyone who suspects a side effect from Ozempic or any other drug or product can report it to the FDA through MedWatch.